Glenmark Pharma reports Q4 FY25 PAT at Rs. 346.6 Cr
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
EBITDA before special items decreases to €4.08 billion (7.4%)
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Subscribe To Our Newsletter & Stay Updated